LGND
Ligand Pharmaceuticals Incorporated
Biotechnology · Healthcare · United States
288.82
close · 2026-08-13
value
30
cheaper than peers30
quality
69
stronger fundamentals69
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 5.95× | 46 |
| forward P/E | 24.13× | 38 |
| price to sales | 22.09× | 36 |
| EV to EBITDA | 42.34× | 27 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 22.0% | 84 |
| operating margin | 13.5% | 78 |
| revenue growth | 33.7% | 53 |
| debt to equity | 116.4% | 21 |
4 of 4 measures available
Facts
| market cap | $6B |
| free cash flow | $142.1M |
| employees | 47 |
| first trade | 1992-11-18 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-10 |